Європейський Союз - англійська - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.

Європейський Союз - англійська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs over the age of two weeks against porcine circovirus type 2 (pcv2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with pcv2-related disease (pcvd).in addition, vaccination has been shown to reduce pcv2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.onset of protection occurs as early as two weeks post vaccination and lasts for at least 17 weeks.

Європейський Союз - англійська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs with no pcv2 maternally derived antibodies from the age of 2 weeks against porcine circovirus type 2 (pcv2),

Європейський Союз - англійська - EMA (European Medicines Agency)

intervet international bv - porcine circovirus type 2 orf2 subunit antigen - immunologicals for suidae - pigs - for the active immunisation of pigs to reduce the virus load in blood and lymphoid tissues and to reduce weight loss associated with porcine-circovirus-type-2 infection occurring during the fattening period.onset of immunity: 2 weeksduration of immunity: 22 weeks

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - porcine circovirus type 2 orf2 protein - unknown - porcine circovirus type 2 orf2 protein vaccine-viral active 0.0 - active constituent

Філіппіни - англійська - FDA (Food And Drug Administration)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - modified live porcine respiratory and reproductive syndrome (prrs) virus , inactivated porcine circovirus type 2 (pcv2) , mesomycoplasma hyopneumoniae vaccine (vet.) - freeze-dried powder for injection (im) - formulation: each 2 ml (dose) contains: porcine circovirus type 2, orf 2........................>1 rp mesomycoplasma hyopneumoniae (b-3745 isolate, j strain) ......... > 1 rp porcine reproductive and respiratory syndrom virus (vr-2332 strain) ........ > 10^5.7 tcid 50 rp - relative potency tcid- tissue culture infective dose

Європейський Союз - англійська - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - porcine circovirus type 2 orf2 subunit antigen - misc. vaccines or anti sera - porcine circovirus type 2 orf2 subunit antigen vaccine-viral active 2.0 mg/2ml - immunotherapy

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - porcine circovirus type 2 orf2 subunit antigen; mycoplasma hyopneumoniae - inactivated antigen - vaccine or antisera - porcine circovirus type 2 orf2 subunit antigen vaccine-viral active 1414.0 au/ml; mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 2.69 rp - immunotherapy

Європейський Союз - англійська - EMA (European Medicines Agency)

zoetis belgium sa - porcine circovirus vaccine (inactivated, recombinant) - immunologicals for suidae, inactivated viral vaccines - pigs (for fattening) - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.,